Treatment of juvenile myasthenia gravis.

07:00 EST 1st January 2019 | BioPortfolio

Summary of "Treatment of juvenile myasthenia gravis."

Juvenile myasthenia gravis is a rare autoimmune disease, which has made it difficult to collect data from prospective randomized controlled trials to evaluate the efficacy and results of different treatments. Although there are differences between the juvenile myasthenia gravis and that of the adult, the data provided by some researches in adults in the treatment of juvenile myasthenia gravis have been used. The different therapeutic options will be evaluated, with the different evidences that sustain it and a treatment algorithm will be elaborated keeping always in mind that each patient offers us different challenges.


Journal Details

This article was published in the following journal.

Name: Medicina
ISSN: 1669-9106
Pages: 71-76


DeepDyve research library

PubMed Articles [16818 Associated PubMed Articles listed on BioPortfolio]

The placebo response in myasthenia gravis assessed by Quantitative Myasthenia Gravis score: A meta-analysis.

This meta-analysis investigates the placebo response in generalized myasthenia gravis (MG) trials by means of Quantitative Myasthenia Gravis (QMG) scores.

Cross-Sectional Analysis of the Myasthenia Gravis Patient Registry: Disability and Treatment.

The Myasthenia Gravis (MG) Patient Registry (MGR) is a voluntary, patient-submitted database dedicated to improve understanding of care/burden of MG.

Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients with Positive Acetylcholine Receptor Antibody.

To evaluate associated factors of conversion of ocular myasthenia gravis (OMG) to generalized myasthenia gravis (GMG) among patients with seropositive acetylcholine receptor antibody (AchR Ab).

Refractory Myasthenia gravis: characteristics of a Portuguese cohort.

Some myasthenia gravis (MG) patients are refractory to conventional treatments.

Outcomes After Transcervical Thymectomy for Ocular Myasthenia Gravis: A Retrospective Cohort Study With Inverse Probability Weighting.

The benefit of thymectomy in reducing requirement for corticosteroids, symptom severity, need for immunosuppression, and hospitalization rates in patients with seropositive generalized myasthenia has ...

Clinical Trials [1250 Associated Clinical Trials listed on BioPortfolio]

Clinical Prognosis and Progression of Myasthenia Gravis Patients

This study collects the clinical data of myasthenia gravis (MG) patients, assesses outcomes and adverse effects of different treatment regimens, and searches for risk factors of conversion...

Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis

The study is being done with patients with Myasthenia Gravis (MG), age 18-80 years, positive acetylcholine receptor antibody, receiving greater than 30mg of prednisone daily. Patients may...

Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis

This study is a double-blind, placebo-controlled, randomized clinical trial to determine whether IVIG is effective in improving motor scores in patients with myasthenia gravis and worsenin...

Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis

This is an randomized, double-blind, double-dummy trial, and the objective is to compare the efficacy and safety of Mycophenolic acid (MA) and Azathioprine (AZA), immunosuppressive drugs, ...

A Study of RVT-1401 in Myasthenia Gravis Patients

The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG an...

Medical and Biotech [MESH] Definitions

A disorder of neuromuscular transmission that occurs in a minority of newborns born to women with myasthenia gravis. Clinical features are usually present at birth or develop in the first 3 days of life and consist of hypotonia and impaired respiratory, suck, and swallowing abilities. This condition is associated with the passive transfer of acetylcholine receptor antibodies through the placenta. In the majority of infants the myasthenic weakness resolves (i.e., transient neonatal myasthenia gravis) although this disorder may rarely continue beyond the neonatal period (i.e., persistent neonatal myasthenia gravis). (From Menkes, Textbook of Child Neurology, 5th ed, p823; Neurology 1997 Jan;48(1):50-4)

Any autoimmune animal disease model used in the study of MYASTHENIA GRAVIS. Injection with purified neuromuscular junction acetylcholine receptor (AChR) (see RECEPTORS, CHOLINERGIC) components results in a myasthenic syndrome that has acute and chronic phases. The motor endplate pathology, loss of acetylcholine receptors, presence of circulating anti-AChR antibodies, and electrophysiologic changes make this condition virtually identical to human myasthenia gravis. Passive transfer of AChR antibodies or lymphocytes from afflicted animals to normals induces passive transfer experimental autoimmune myasthenia gravis. (From Joynt, Clinical Neurology, 1997, Ch 54, p3)


A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.

Human immune-response, D-related antigen encoded by the D locus on chromosome 6 and found on lymphoid cells. It is in linkage disequilibrium with HLA-A1 and HLA-B8. The HLA-DR3 antigen is strongly associated with celiac disease, Grave's disease, dermatitis herpetiformis, early-age onset myasthenia gravis, systemic lupus erythematosus, juvenile diabetes, and opportunistic infections in AIDS.

Quick Search
DeepDyve research library

Relevant Topic

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Searches Linking to this Article